November 6, 2019
Camallergy Provides Corporate Update and Prepares to Advance Lead Candidate CA002 Into Phase 3 Efficacy Trial for Peanut Allergy
-Phase 3 development program aligned with FDA feedback, supporting development path to BLA -Pivotal Phase 3 clinical efficacy trial planned…